Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2025 Financial Results
Sonoma Pharmaceuticals (NASDAQ:SNOA) reported strong Q2 FY2025 results with significant improvements across key metrics. Revenue increased 31% to $3.6 million, driven by growth in US (14%), Europe (25%), and Latin America (79%). The company reduced its net loss by 59% to $0.6 million, while achieving positive cash flows from operations of $0.35 million. Gross profit margin improved to 38% from 36% year-over-year. The company strengthened its market position through new distribution agreements for wound care products in the US and Canada, and received FDA clearance for expanded eye care and dermatological product indications.
Sonoma Pharmaceuticals (NASDAQ:SNOA) ha riportato risultati forti per il secondo trimestre dell'anno fiscale 2025, con miglioramenti significativi in vari indicatori chiave. I ricavi sono aumentati del 31% raggiungendo $3,6 milioni, grazie alla crescita negli Stati Uniti (14%), in Europa (25%) e in America Latina (79%). L'azienda ha ridotto la sua perdita netta del 59%, portandola a $0,6 milioni, mentre ha ottenuto flussi di cassa positivi dalle operazioni pari a $0,35 milioni. Il margine di profitto lordo è migliorato al 38% rispetto al 36% dell'anno precedente. La società ha rafforzato la sua posizione di mercato grazie a nuovi accordi di distribuzione per prodotti per la cura delle ferite negli Stati Uniti e in Canada, e ha ricevuto l'approvazione della FDA per l'espansione delle indicazioni dei prodotti per la cura degli occhi e dermatologici.
Sonoma Pharmaceuticals (NASDAQ:SNOA) reportó resultados sólidos para el segundo trimestre del año fiscal 2025, con mejoras significativas en métricas clave. Los ingresos aumentaron un 31%, alcanzando $3,6 millones, impulsados por el crecimiento en EE. UU. (14%), Europa (25%) y América Latina (79%). La compañía redujo su pérdida neta en un 59%, llevándola a $0,6 millones, mientras lograba flujos de efectivo positivos de operaciones por $0,35 millones. El margen de beneficio bruto mejoró al 38% desde el 36% en comparación con el año anterior. La empresa fortaleció su posición en el mercado a través de nuevos acuerdos de distribución para productos de cuidado de heridas en EE. UU. y Canadá, y recibió la autorización de la FDA para ampliar las indicaciones de productos para cuidado de los ojos y dermatológicos.
소노마 제약 (NASDAQ:SNOA)는 2025 회계 연도 2분기 결과를 발표하였으며, 주요 지표에서 실질적인 개선을 보여주었습니다. 수익은 31% 증가하여 $3.6 백만에 도달하였으며, 이는 미국(14%), 유럽(25%) 및 라틴 아메리카(79%)의 성장이 기여했습니다. 회사는 순손실을 59% 줄여 $0.6 백만에 이르렀고, 운영으로부터의 긍정적인 현금 흐름은 $0.35 백만에 달했습니다. 총 이익률은 전년 대비 36%에서 38%로 개선되었습니다. 회사는 미국과 캐나다에서 상처 치료 제품에 대한 새로운 유통 계약을 통해 시장 내 입지를 강화했으며, 안과 및 피부과 제품 적응증 확대를 위해 FDA 승인을 받았습니다.
Sonoma Pharmaceuticals (NASDAQ:SNOA) a annoncé de solides résultats pour le deuxième trimestre de l'exercice 2025, avec des améliorations significatives dans les indicateurs clés. Le chiffre d'affaires a augmenté de 31% pour atteindre $3,6 millions, soutenu par la croissance aux États-Unis (14%), en Europe (25%) et en Amérique latine (79%). L'entreprise a réduit sa perte nette de 59%, atteignant $0,6 millions, tout en réalisant des flux de trésorerie positifs d'exploitation de $0,35 millions. La marge brute de profit s'est améliorée, passant de 36% à 38% par rapport à l'année précédente. La société a renforcé sa position sur le marché grâce à de nouveaux accords de distribution pour des produits de soins des plaies aux États-Unis et au Canada, et a obtenu l'approbation de la FDA pour l'élargissement des indications de produits de soins oculaires et dermatologiques.
Sonoma Pharmaceuticals (NASDAQ:SNOA) meldete starke Ergebnisse für das zweite Quartal des Geschäftsjahres 2025 mit signifikanten Verbesserungen in den wichtigsten Kennzahlen. Der Umsatz stieg um 31% auf 3,6 Millionen USD, angetrieben durch das Wachstum in den USA (14%), Europa (25%) und Lateinamerika (79%). Das Unternehmen hat seinen Nettoverlust um 59% auf 0,6 Millionen USD reduziert, während es positive Cashflows aus dem operativen Geschäft von 0,35 Millionen USD erzielte. Die Bruttogewinnmarge verbesserte sich von 36% auf 38% im Vergleich zum Vorjahr. Das Unternehmen stärkte seine Marktposition durch neue Vertriebsvereinbarungen für Wundversorgungsprodukte in den USA und Kanada und erhielt die FDA-Zulassung für erweiterte Indikationen für Augenpflege- und dermatologische Produkte.
- Revenue increased 31% YoY to $3.6 million
- Net loss decreased 59% YoY to $0.6 million
- Positive operating cash flow of $0.35 million
- Gross profit margin improved to 38% from 36%
- Cash position increased by $2 million YoY to $4.1 million
- Strong regional growth: US +14%, Europe +25%, Latin America +79%
- Still operating at a net loss of $0.6 million
- US revenue declined 6% for the six-month period
Insights
The Q2 FY2025 results demonstrate significant operational improvements for Sonoma Pharmaceuticals. Revenue growth of
Most notably, the net loss decreased by
The strategic expansion of Sonoma's distribution network and product portfolio strengthens its market position. The new partnership with a leading global healthcare distributor opens significant opportunities in the US and Canadian wound care markets. The FDA's 510(k) clearance for OTC indications in face and eye care expands the addressable market.
Geographic revenue diversification is improving, with strong growth in Europe and Latin America offsetting regional fluctuations. The company's ability to maintain stable operating expenses while growing revenue demonstrates operational leverage. The Australian TGA approval for extended claims against C. auris and C. diff adds competitive advantages in hospital and healthcare settings. These developments indicate improving market penetration and brand recognition across key territories.
Revenue increased
31% for the quarter compared to same period prior yearPositive cash flows from operations of
$0.35 million for the quarterNet loss improved
59% for the quarter compared to same period prior yearNet loss per share improved
90% for the quarter compared to same period prior year
BOULDER, CO / ACCESSWIRE / November 7, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA),a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced financial results for its second fiscal quarter ended September 30, 2024.
"Our results this quarter reflect the diligent efforts by Sonoma's team to grow our business and drive toward profitability," said Amy Trombly, CEO of Sonoma. "Revenues were up
Business Highlights
Sonoma continued to improve and expand its product offerings and regulatory approvals, and to grow its distribution network by entering into new partnerships:
On August 19, 2024, Sonoma entered into a distribution agreement with a leading global healthcare distributor for the marketing and distribution of its wound care products in the United States. On October 17, 2024, Sonoma entered into an amendment this agreement to allow for the marketing and distribution of its wound care products in Canada, and to add over-the-counter wound care products for sale in both countries.
On September 13, 2024, Sonoma received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Microcyn technology-based solution, including specific over-the-counter indications for the face, eyelid and eyelashes.
On September 11, 2024, Sonoma announced an expanded prescription and over-the-counter eye care product line, featuring a refreshed design and improved packaging for Ocucyn ® Eyelid & Eyelash Cleanser.
On August 26, 2024, Sonoma and its partner, the MicroSafe Group DMCC, announced that the Australian Therapeutic Goods Administration (TGA) had approved extended claims for Nanocyn ® Disinfectant and Sanitizer for effective use against Candida auris (C. auris) and Clostritium Difficile (C. diff.).
Results for the Quarter Ended September 30, 2024
Total revenues for the quarter ended September 30, 2024 of
During the quarter ended September 30, 2024, Sonoma reported revenues of
Total operating expenses during the quarter ended September 30, 2024 were
Net loss for the three months ended September 30, 2024 of
Results for the Six Months Ended September 30, 2024
Total revenues for the six months ended September 30, 2024 of
During the six months ended September 30, 2024, Sonoma reported revenues of
Total operating expenses during the six months ended September 30, 2024 were
Net loss for the six months ended September 30, 2024 of
As of September 30, 2024, Sonoma had cash and cash equivalents of
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "reduce," "develop," "aim," and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs or fund further development, as well as uncertainties relative to the recent pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals™, Microcyn ®, Ocucyn ®, and Nanocyn ® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
Website: https://www.sonomapharma.com
Follow us on LinkedIn: https://www.linkedin.com/company/sonoma-pharmaceuticals
Follow us on Instagram: https://www.instagram.com/sonomapharma_us/
Follow us on Facebook: https://www.facebook.com/sonomapharma/
SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(In thousands, except share amounts)
| September 30, 2024 |
|
| March 31, 2024 |
| |||
| (Unaudited) |
|
|
|
| |||
ASSETS |
|
|
|
|
|
| ||
Current assets: |
|
|
|
|
|
| ||
Cash and cash equivalents |
| $ | 4,078 |
|
| $ | 3,128 |
|
Accounts receivable, net |
|
| 3,157 |
|
|
| 2,898 |
|
Inventories, net |
|
| 2,837 |
|
|
| 2,719 |
|
Prepaid expenses and other current assets |
|
| 1,929 |
|
|
| 3,541 |
|
Current portion of deferred consideration, net of discount |
|
| 220 |
|
|
| 262 |
|
Total current assets |
|
| 12,221 |
|
|
| 12,548 |
|
Property and equipment, net |
|
| 255 |
|
|
| 365 |
|
Operating lease, right of use assets |
|
| 162 |
|
|
| 286 |
|
Deferred tax asset |
|
| 792 |
|
|
| 1,145 |
|
Deferred consideration, net of discount, less current portion |
|
| 179 |
|
|
| 330 |
|
Other assets |
|
| 76 |
|
|
| 66 |
|
Total assets |
| $ | 13,685 |
|
| $ | 14,740 |
|
|
|
|
|
|
|
|
| |
LIABILITIES AND STOCKHOLDERS' EQUITY |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable |
| $ | 770 |
|
| $ | 607 |
|
Accrued expenses and other current liabilities |
|
| 2,022 |
|
|
| 2,113 |
|
Deferred revenue, current portion |
|
| 319 |
|
|
| 478 |
|
Short-term debt |
|
| 82 |
|
|
| 323 |
|
Operating lease liabilities, current portion |
|
| 116 |
|
|
| 198 |
|
Total current liabilities |
|
| 3,309 |
|
|
| 3,719 |
|
Deferred revenue, net of current portion |
|
| 45 |
|
|
| 87 |
|
Withholding tax payable |
|
| 4,933 |
|
|
| 4,710 |
|
Operating lease liabilities, less current portion |
|
| 46 |
|
|
| 87 |
|
Total liabilities |
|
| 8,333 |
|
|
| 8,603 |
|
Commitments and Contingencies (Note 5) |
|
|
|
|
|
|
|
|
Stockholders' Equity: |
|
|
|
|
|
|
|
|
Convertible preferred stock, |
|
| - |
|
|
| - |
|
Common stock, |
|
| - |
|
|
| - |
|
Additional paid-in capital |
|
| 205,651 |
|
|
| 203,209 |
|
Accumulated deficit |
|
| (196,102 | ) |
|
| (194,349 | ) |
Accumulated other comprehensive loss |
|
| (4,197 | ) |
|
| (2,723 | ) |
Total stockholders' equity |
|
| 5,352 |
|
|
| 6,137 |
|
Total liabilities and stockholders' equity |
| $ | 13,685 |
|
| $ | 14,740 |
|
SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Comprehensive Loss
(In thousands, except per share amounts)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
| Three Months Ended |
|
| Six Months Ended |
| ||||||||||
|
| 2024 |
|
| 2023 |
|
| 2024 |
|
| 2023 |
| ||||
Revenues |
| $ | 3,579 |
|
| $ | 2,731 |
|
| $ | 6,970 |
|
| $ | 6,158 |
|
Cost of revenues |
|
| 2,218 |
|
|
| 1,741 |
|
|
| 4,303 |
|
|
| 3,964 |
|
Gross profit |
|
| 1,361 |
|
|
| 990 |
|
|
| 2,667 |
|
|
| 2,194 |
|
Operating expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
| 506 |
|
|
| 536 |
|
|
| 976 |
|
|
| 861 |
|
Selling, general and administrative |
|
| 1,705 |
|
|
| 1,662 |
|
|
| 3,714 |
|
|
| 3,781 |
|
Total operating expenses |
|
| 2,211 |
|
|
| 2,198 |
|
|
| 4,690 |
|
|
| 4,642 |
|
Loss from operations |
|
| (850 | ) |
|
| (1,208 | ) |
|
| (2,023 | ) |
|
| (2,448 | ) |
Other income (expense), net |
|
| 387 |
|
|
| (90 | ) |
|
| 563 |
|
|
| (301 | ) |
Loss from operations before income taxes |
|
| (463 | ) |
|
| (1,298 | ) |
|
| (1,460 | ) |
|
| (2,749 | ) |
Income tax expense |
|
| (147 | ) |
|
| (186 | ) |
|
| (293 | ) |
|
| (153 | ) |
Net loss |
| $ | (610 | ) |
| $ | (1,484 | ) |
| $ | (1,753 | ) |
| $ | (2,902 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share: basic and diluted |
| $ | (0.59 | ) |
| $ | (5.75 | ) |
| $ | (1.86 | ) |
| $ | (11.47 | ) |
Weighted-average number of shares: basic and diluted |
|
| 1,034 |
|
|
| 258 |
|
|
| 943 |
|
|
| 253 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
| $ | (610 | ) |
| $ | (1,484 | ) |
| $ | (1,753 | ) |
| $ | (2,902 | ) |
Foreign currency translation adjustments |
|
| (593 | ) |
|
| (213 | ) |
|
| (1,474 | ) |
|
| 298 |
|
Comprehensive loss |
| $ | (1,203 | ) |
| $ | (1,697 | ) |
| $ | (3,227 | ) |
| $ | (2,604 | ) |
SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
RECONCILIATION OF GAAP MEASURES TO NON-GAAP MEASURES
(In thousands)
(Unaudited)
|
| Three Months Ended |
|
| Six Months Ended |
| ||||||||||
|
| 2024 |
|
| 2023 |
|
| 2024 |
|
| 2023 |
| ||||
(1) Net loss adjusted for non-cash items and one-time events or EBITDA loss: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP net loss as reported |
| $ | (610 | ) |
| $ | (1,484 | ) |
| $ | (1,753 | ) |
| $ | (2,902 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-cash adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation |
|
| 14 |
|
|
| 130 |
|
|
| 121 |
|
|
| 307 |
|
Non-cash foreign exchange transaction losses (gains) |
|
| (225 | ) |
|
| 108 |
|
|
| (402 | ) |
|
| 367 |
|
Income tax expense |
|
| 147 |
|
|
| 186 |
|
|
| 293 |
|
|
| 153 |
|
Depreciation and amortization |
|
| 35 |
|
|
| 45 |
|
|
| 74 |
|
|
| 90 |
|
Non-GAAP net loss adjusted for non-cash items and one-time events or EBITDA loss |
| $ | (639 | ) |
| $ | (1,015 | ) |
| $ | (1,667 | ) |
| $ | (1,985 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2) Operating expenses minus non-cash expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP operating expenses as reported |
| $ | 2,211 |
|
| $ | 2,198 |
|
| $ | 4,690 |
|
| $ | 4,642 |
|
Non-cash adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation |
|
| (14 | ) |
|
| (130 | ) |
|
| (121 | ) |
|
| (307 | ) |
Depreciation and amortization |
|
| (35 | ) |
|
| (45 | ) |
|
| (74 | ) |
|
| (90 | ) |
Non-GAAP operating expenses minus non-cash expenses |
| $ | 2,162 |
|
| $ | 2,023 |
|
| $ | 4,495 |
|
| $ | 4,245 |
|
Net loss adjusted for non-cash items and one-time events, or EBITDA loss, is a non-GAAP financial measure. The Company defines this as GAAP reported net loss minus depreciation and amortization, stock-based compensation, income taxes and non-cash foreign exchange transaction losses. The Company uses this measure for the purpose of modifying the net loss to reflect only those expenses to reflect normal direct cash transactions during the measurement period. Non-GAAP measures should not be considered a substitute for financial measures presented in accordance with GAAP. Non-GAAP measures are not always consistent across, or comparable with, non-GAAP measures disclosed by other companies.
Operating expenses minus non-cash expenses is a non-GAAP financial measure. The Company defines operating expenses minus non-cash expenses as GAAP reported operating expenses minus operating depreciation and amortization, and operating stock-based compensation. The Company uses this measure for the purpose of identifying total operating expenses involving cash transactions during the measurement period. Non-GAAP measures should not be considered a substitute for financial measures presented in accordance with GAAP. Non-GAAP measures are not always consistent across, or comparable with, non-GAAP measures disclosed by other companies.
SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
PRODUCT RELATED REVENUE SCHEDULES
(In thousands)
(Unaudited)
The following table shows our consolidated total revenue and revenue by geographic region for the three and six months ended September 30, 2024 and 2023:
| Three Months Ended September 30, |
|
|
|
|
|
|
| ||||||||
(In thousands) |
| 2024 |
|
| 2023 |
|
| $ Change |
|
| % Change |
| ||||
United States |
| $ | 675 |
|
| $ | 590 |
|
| $ | 85 |
|
|
| 14 | % |
Europe |
|
| 1,506 |
|
|
| 1,201 |
|
|
| 305 |
|
|
| 25 | % |
Asia |
|
| 776 |
|
|
| 346 |
|
|
| 430 |
|
|
| 124 | % |
Latin America |
|
| 465 |
|
|
| 260 |
|
|
| 205 |
|
|
| 79 | % |
Rest of the World |
|
| 157 |
|
|
| 334 |
|
|
| (177 | ) |
|
| (53 | %) |
Total |
| $ | 3,579 |
|
| $ | 2,731 |
|
| $ | 848 |
|
|
| 31 | % |
| Six Months Ended September 30, |
|
|
|
|
|
|
| ||||||||
(In thousands) |
| 2024 |
|
| 2023 |
|
| $ Change |
|
| % Change |
| ||||
United States |
| $ | 1,317 |
|
| $ | 1,396 |
|
| $ | (79 | ) |
|
| (6 | %) |
Europe |
|
| 2,794 |
|
|
| 2,271 |
|
|
| 523 |
|
|
| 23 | % |
Asia |
|
| 1,253 |
|
|
| 1,208 |
|
|
| 45 |
|
|
| 4 | % |
Latin America |
|
| 1,345 |
|
|
| 747 |
|
|
| 598 |
|
|
| 80 | % |
Rest of the World |
|
| 261 |
|
|
| 536 |
|
|
| (275 | ) |
|
| (51 | %) |
Total |
| $ | 6,970 |
|
| $ | 6,158 |
|
| $ | 812 |
|
|
| 13 | % |
SOURCE: Sonoma Pharmaceuticals, Inc.
View the original press release on accesswire.com
FAQ
What was Sonoma Pharmaceuticals (SNOA) revenue growth in Q2 2025?
How much did SNOA reduce its net loss in Q2 2025?
What new regulatory approvals did SNOA receive in Q2 2025?